Genome-Wide Association Study of Parkinson Disease

Parkinson's disease (PD) is a common, progressive, age-related, movement disorder that affects 1-2% of the people over the age of 65. The NeuroGenetics Research Consortium (NGRC) is the infrastructure of the study. Study subjects were recruited at NGRC-affiliated movement disorder clinics in Oregon, Washington, Georgia, New York, and Alabama. DNA was extracted from blood or saliva, and unamplified DNA was genotyped on Illumina platforms. Protocols and methods were standardized across NGRC clinics and labs. Genotypes and phenotypes were uploaded to dbGaP (phs000196). Gut microbiome 16S amplicon sequencing results were uploaded to NCBI's Sequence Read Archive under BioProject ID PRJNA601994.

• Study Design:
  • Case-Control
• Study Type:
  • Case-Control
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 4011
• Subject Sample Telemetry Report (SSTR)

CASE

NGRC Enrollment Criteria

1. Informed consent
2. Diagnosis of PD by a neurologist using modified UK Brain Bank criteria (modified in that patients with a positive family history are not excluded)
3. Genetically unrelated to all other patients and all controls
4. Donate tissue for DNA extraction
5. Fill out environmental exposure questionnaire, EEQ implemented in 2004

Additional GWAS Inclusion Criteria

1. IRB/Institutional Certification for data sharing via dbGaP
2. Exclude if diagnosis known to have changed after enrollment to not PD
3. Age at blood draw ≥ 20 yrs
4. Known self-reported gender
5. Unamplified DNA from whole blood or saliva

CONTROL

NGRC Enrollment Criteria

1. Informed consent
2. No neurologic disorder at enrollment, by self report or exam, including Alzheimer's, Bipolar, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Ataxia, Dystonia, Parkinson's, Autism, Dementia, Epilepsy and Schizophrenia
3. Genetically unrelated to all patients and all other controls
4. Donate tissue for DNA extraction
5. Fill out EEQ implemented in 2004

Additional GWAS Inclusion Criteria

1. IRB/Institutional Certification for data sharing via dbGaP
2. Exclude if known to have developed PD or essential tremor after enrollment
3. Age at blood draw ≥ 20 yrs
4. Known self-reported gender
5. Unamplified DNA from whole blood or saliva

NeuroGenetics Research Consortium (NGRC) began as a genetic study of PD in Oregon in the 1990's and has since grown to include collaborations at several academic, federal and state institutions. The genetic arm of the study was funded by NIH since 1998 (R01 NS36960, Haydeh Payami, PI). In 2004, the consortium was formalized as a Michael J Fox Foundation Funded Global Genetic Consortium, and an epidemiologic arm was implemented allowing gene-environment studies. In 2015, a gut microbiome arm was added. NGRC includes eight movement disorder clinics in five states, led by Drs. Stewart Factor (Emory University), Haydeh Payami (Oregon Health & Sciences University), Cyrus Zabetian (University of Washington and Puget Sound Veterans Medical Center), Eric Molho (Albany Medical College), and David Standaert and Haydeh Payami (University of Alabama at Birmingham). NGRC's molecular and statistical genetics laboratories are at University of Alabama at Birmingham (Haydeh Payami) and Puget Sound Veterans Medical Center (Cyrus Zabetian).

• Primary Phenotype: Parkinson Disease

• BioProject
• PubMed
• BioSample
• MeSH
• PMC

• Principal Investigator
  • Haydeh Payami, PhD. University of Alabama at Birmingham.
• Funding Source     
  • 5R01NS36960-10. National Institutes of Health, Bethesda, MD, USA.
• Funding Source
  • No number. University of Alabama at Birmingham.
• Co-Investigator
  • Stewart Factor, DO. Emory University.
  • Cyrus Zabetian, MS, MD. University of Washington and Puget Sound Veterans Medical Center.
  • Eric Molho, MD. Albany Medical Center.
  • David Standaert, MD, PhD. University of Alabama at Birmingham.